FDA clears Protagonist-Takeda therapy for rare blood cancer as Lilly moves to buy Merida for up to $2.88 billion

The U.S. Food and Drug Administration has granted approval to a collaborative therapy from Protagonist and Takeda aimed at treating a rare form of blood cancer.

This regulatory decision adds a new option for patients facing this uncommon disease and reflects progress in targeted oncology treatments.

In a separate development, Eli Lilly announced plans to acquire Merida in a deal valued at up to $2.88 billion, signaling a strategic expansion of its portfolio.